These data imply that trimebutine may inhibit the PI3K/AKT and MAPK/ERK signaling pathways to attenuate proliferation and promote cell apoptosis in glioma cells, thus leading to the inhibition of cell migration and colony formation. This evidence concerns the gene AKT1 and central nervous system cancer.